Excalibur Fund Managers

Overview

Excalibur Fund Managers is a UK-based venture capital firm specializing in life sciences investments across Europe under the Merlin brand. The firm focuses on sectors such as biotechnology, medical devices, and health technology, aiming to bridge the gap between research and commercialization. Excalibur provides both early and late-stage capital to companies innovating in critical areas like oncology, therapeutic devices, and laboratory services. Their investment strategy targets companies that are developing cutting-edge therapies, diagnostics, and healthcare technologies. Excalibur has made over 59 investments, with notable companies like Celsis International, NeoGen, and Selah Genomics. The firm has also facilitated numerous successful exits, including companies like Plethora Solutions and Celsis In Vitro. Excalibur's approach is highly strategic, supporting startups not just with capital but also by offering market access and strategic advice, positioning them for acquisitions or public listings. This makes Excalibur a critical player in the European life sciences venture space, known for its ability to take healthcare innovations from the lab to the marketplace.

Investment Focus

• Focus on life sciences, biotechnology, and medical devices
• Investments in early and late-stage companies
• Targeting companies in oncology, therapeutic devices, and laboratory services
• Preference for companies with innovative therapies, diagnostics, and healthcare technologies
• Interest in companies with potential for acquisitions or public listings

Portfolio Companies